A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adrenocortical carcinoma
- Focus Adverse reactions
- Acronyms ACCOMPLISH
- 23 Nov 2023 Status changed from not yet recruiting to recruiting.
- 18 Feb 2023 Trial design presented at the 2023 Genitourinary Cancers Symposium
- 15 Nov 2021 Planned initiation date changed from 1 Nov 2021 to 15 Nov 2021.